 Correction updates the increase in mean serum TTR levels for variant-carrying ATTR-CM to 56 at OLE Visiting Day 180. BridgeBio Pharma, Inc. BridgeBio Nasdaq:BBIO and Eidos Therapeutics, Inc. Eidos EIDX, today presented positive data from the companies ongoing Open Label Extension OLE of the Phase 2 clinical trial studying AG10 in patients with symptomatic transthyretin TTR amyloidosis cardiomyopathy ATTR-CM. 